

The **Adapt™ Biostable Drug Delivery Platform** is a biocompatible, non-biodegradable polymeric coating, specifically designed for the controlled elution of therapeutic agents in a **controlled** and **site-targeted** manner.


Synthesised from both hydrophilic and hydrophobic monomers, the amphiphilic **Adapt™** system provides exquisite control over drug release and can be easily tailored, through simple adjustment in the monomer ratios, to afford **customised release profiles** and **bespoke physical properties**.



Adaptability

The synthetic protocol employed allows for **complete control** during the polymerisation process and provides scope for the production of an array of different delivery systems, with **customised properties**. As the polymer is designed and tuned to meet the customer's exacting specifications from the out-set, only one final polymer is required. The blending of several different polymers to achieve the final delivery system is not needed, thus **reducing both time and cost**.


The **highly adjustable** nature of the **Adapt™** system means that a variety of different drugs can be employed, including rapamycin and paclitaxel. In addition, a range of drug elution profiles can be achieved.



The Coating Process

The proprietary coating process, developed by scientists at BioInteractions, allows a multitude of devices with various geometries and sizes to be incorporated into the coating process with ease, ensuring **minimal waste** with **maximum efficiency**.

The adjustable nature of **Adapt™** allows for a variety of different substrates to be coated, including stainless steel, cobalt chromium, nitinol, poly(urethane), silicone and many others. The coating process, coupled with the polymer itself, affords a **smooth, homogeneous coating**.



Coronary stent coated with **Adapt™** Biostable Drug Delivery Platform.

Efficiency

The highly efficient nature of the **Adapt™** system towards the release of drugs means that **total elution** of the therapeutic agent is achieved. No drug is retained in the polymer, thus minimising the chance of a late inflammatory response. The coating can be sterilised by ethylene oxide (EtO) sterilisation.

Experience

With many years experience, the team at BioInteractions can assist with **technology transfer** and implementation of the coating process into a manufacturing facility, ensuring efficient and reproducible throughput of the final product.

Collaboration

BioInteractions is committed to the advancement of healthcare through the development of innovative technology and therefore, welcomes interest in the **Adapt™ Biostable Drug Delivery Platform** for application to both existing and new technologies that require the next generation of drug delivery system.